For Research Use Only — Not for Human or Veterinary Use
BPC-157 Refill 10mg is supplied exclusively for in vitro and pre-clinical in vivo research use with the AbsoluteBioLab Reusable Metal Peptide Pen v3. This product has not been evaluated by the MHRA, FDA, or any other regulatory authority for safety or efficacy in humans or animals. Purchase and use of this product confirms that the buyer is a qualified researcher operating within applicable institutional and legal frameworks.
BPC-157 Refill 10mg — Research-Grade Pentadecapeptide Refill Cartridge for the AbsoluteBioLab Peptide Pen v3
The BPC-157 Refill 10mg is a pre-filled lyophilised refill cartridge containing research-grade BPC-157 (Body Protection Compound-157), a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 amino acids), derived from a gastroprotective region of the human gastric juice protein BPC. This refill format is engineered for direct use with the AbsoluteBioLab Reusable Metal Peptide Pen v3, providing a convenient, reproducible, and cost-effective format for pre-clinical research programmes requiring repeated, precisely dosed administration of BPC-157.
Each refill cartridge contains 10mg of lyophilised BPC-157 acetate salt, verified by reverse-phase high-performance liquid chromatography (RP-HPLC) to a minimum purity of ≥99.0%, with molecular identity confirmed by electrospray ionisation mass spectrometry (ESI-MS). Endotoxin content is tested by kinetic turbidimetric Limulus Amebocyte Lysate (LAL) assay and certified at <1.0 EU/mg. Residual moisture is verified by Karl Fischer titration at <5.0%. A batch-specific Certificate of Analysis (CoA) is included with every order.
BPC-157 was first characterised by Professor Predrag Sikiric and colleagues at the University of Zagreb, where it was isolated as the active fragment of a larger gastric juice protein. Subsequent pre-clinical research spanning more than three decades has demonstrated that BPC-157 exhibits potent tissue repair activity across multiple organ systems — including the gastrointestinal tract, musculoskeletal system, nervous system, and cardiovascular system — through mechanisms involving VEGFR2 activation, FAK/paxillin signalling, NO-cGMP modulation, and GHR/JAK2 pathway interactions. The compound is stable in gastric juice and resistant to proteolytic degradation, properties that have made it one of the most widely studied synthetic peptides in pre-clinical tissue repair research.
Compound Identity & Molecular Data
| Parameter | Value |
|---|---|
| Compound Name | BPC-157 (Body Protection Compound-157) |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Residue Count | 15 amino acids (pentadecapeptide) |
| Molecular Formula | C₆₂H₉₈N₁₆O₂₂ |
| Molecular Weight | 1,419.55 Da (free base, monoisotopic) |
| CAS Number | 137525-51-0 |
| Salt Form | Acetate salt (lyophilised) |
| Structural Features | Linear; no disulphide bonds; proline-rich N-terminal region |
| Primary Targets | VEGFR2, FAK/paxillin, eNOS/nNOS, GHR/JAK2 |
| Research Classification | Tissue repair peptide; gastroprotective; angiogenic |
Analytical Release Testing — Refill Cartridge Specification
| Test | Method | Specification | Notes |
|---|---|---|---|
| Purity | RP-HPLC (C18, UV 220 nm) | ≥99.0% | Acetonitrile/water gradient; TFA modifier |
| Identity | ESI-MS | Confirmed ±0.1 Da | Expected [M+H]⁺: 1,420.56; [M+2H]²⁺: 710.78 |
| Endotoxin | Kinetic turbidimetric LAL | <1.0 EU/mg | Chromogenic LAL assay; USP <85> compliant method |
| Residual Moisture | Karl Fischer titration | <5.0% | Coulometric KF; ensures lyophilisation quality |
| Quantity per Cartridge | Gravimetric | 10 mg ± 5% | Lyophilised acetate salt; net peptide content |
| Compatible Device | — | AbsoluteBioLab Peptide Pen v3 | Use with 4mm 31G pen needles; bacteriostatic water for reconstitution |
Mechanism of Action — Multi-Target Tissue Repair Signalling
BPC-157 exerts its tissue repair effects through a well-characterised multi-target signalling profile that distinguishes it from single-pathway peptides. The primary mechanism involves activation of VEGFR2 (vascular endothelial growth factor receptor 2) signalling in endothelial cells and fibroblasts, promoting angiogenesis, endothelial cell proliferation, and tube formation in in vitro wound healing models. VEGFR2 activation by BPC-157 leads to downstream phosphorylation of ERK1/2, Akt, and eNOS, driving both cell survival and nitric oxide production that supports vascular remodelling at sites of tissue injury.
BPC-157 also activates the focal adhesion kinase (FAK)/paxillin pathway, which regulates cell migration and adhesion — processes critical for wound closure and tissue repair. FAK phosphorylation at Tyr397 by BPC-157 promotes lamellipodia formation and directional cell migration in scratch assay models, with effects observed in fibroblasts, keratinocytes, and smooth muscle cells. This FAK/paxillin activation is thought to be mediated through integrin signalling, as BPC-157 has been shown to modulate integrin expression and clustering in cell adhesion models.
In gastrointestinal research models, BPC-157 modulates the nitric oxide (NO)-cGMP signalling axis with a dual effect on NOS isoforms: it upregulates eNOS expression in endothelial cells (promoting gastroprotective NO production) while modulating nNOS activity in enteric neurons (contributing to its effects on gastrointestinal motility and mucosal healing). This NO-cGMP modulation is central to BPC-157’s well-documented gastroprotective activity in rodent models of ethanol-induced, NSAID-induced, and stress-induced gastric ulceration.
BPC-157 also interacts with the growth hormone receptor (GHR) signalling pathway, activating JAK2/STAT5 downstream of GHR and promoting IGF-1 expression in musculoskeletal tissue models. This GHR interaction is thought to contribute to BPC-157’s effects on tendon, ligament, and bone healing in pre-clinical models, where it has been shown to accelerate collagen synthesis, fibroblast proliferation, and extracellular matrix remodelling. The compound’s resistance to proteolytic degradation — attributed to its proline-rich N-terminal sequence — ensures that it remains biologically active in the complex protease-rich environment of healing tissue.
Research Applications
BPC-157 is used across a broad range of pre-clinical research disciplines. In gastrointestinal research, BPC-157 is employed in rodent models of gastric ulceration (ethanol, indomethacin, cysteamine, stress-induced), inflammatory bowel disease (DSS-induced colitis, TNBS colitis), and intestinal anastomosis healing, where it consistently demonstrates mucosal protection and accelerated healing. In musculoskeletal research, BPC-157 is studied in tendon transection, ligament rupture, bone fracture, and muscle crush injury models, where it promotes fibroblast proliferation, collagen synthesis, and extracellular matrix remodelling. In neurological research, BPC-157 has been studied in models of traumatic brain injury, spinal cord injury, and peripheral nerve damage, where it promotes axonal regrowth and reduces neuroinflammation through VEGFR2 and NO-cGMP mechanisms.
In cardiovascular research, BPC-157 is used in models of myocardial infarction, cardiac arrhythmia, and vascular injury, where it promotes angiogenesis and reduces ischaemia-reperfusion injury through VEGFR2 and eNOS activation. The refill cartridge format is particularly suited to research programmes requiring repeated subcutaneous or intramuscular administration over extended time courses, as it provides a consistent, pre-measured dose in a convenient pen-delivery format that minimises handling and reconstitution variability between doses.
Refill Cartridge vs Full Vial — Choosing the Right Format
The BPC-157 Refill 10mg is designed specifically for use with the AbsoluteBioLab Reusable Metal Peptide Pen v3, providing a convenient and reproducible delivery format for research programmes that have already adopted the pen system. The refill cartridge format offers several practical advantages over the standard vial format for ongoing research: the pre-filled cartridge eliminates the need for repeated vial reconstitution and syringe loading, reducing the risk of contamination and dosing variability between administrations. The pen delivery system also provides more precise dose control than conventional insulin syringes, with a graduated dial mechanism that allows researchers to set consistent doses across multiple animals or time points.
Researchers who have not yet adopted the pen system, or who require BPC-157 for in vitro assays, cell culture experiments, or non-subcutaneous administration routes, should consider the BPC-157 10mg standard vial format, which provides the same research-grade material in a conventional lyophilised vial suitable for reconstitution in any appropriate buffer. The BPC-157 / TB-500 Blend 10mg is also available for researchers investigating the synergistic tissue repair effects of BPC-157 and TB-500 co-administration.
Reconstitution & Handling Guidance
BPC-157 Refill cartridges are supplied in lyophilised form and must be reconstituted before use. For use with the AbsoluteBioLab Peptide Pen v3, reconstitute the cartridge with bacteriostatic water (0.9% benzyl alcohol in sterile water for injection) to the desired concentration. A typical reconstitution for research use is 2ml bacteriostatic water to yield a 5mg/ml (5,000 μg/ml) solution, allowing precise dose setting via the pen dial. Allow the lyophilised cake to dissolve completely by gentle swirling — do not vortex or shake vigorously, as mechanical agitation can cause peptide aggregation. The reconstituted solution should be clear and colourless; discard if particulate matter or discolouration is observed.
For in vitro research applications, BPC-157 may be reconstituted in sterile phosphate-buffered saline (PBS, pH 7.4) or cell culture-grade water. Working solutions should be prepared fresh from frozen aliquots where possible. BPC-157 is soluble in aqueous buffers at concentrations up to 10mg/ml under standard conditions; higher concentrations may require brief sonication or gentle warming to 37°C to achieve complete dissolution.
Storage & Stability
| Condition | Temperature | Duration | Notes |
|---|---|---|---|
| Lyophilised cartridge (long-term) | −20°C | ≥24 months | Desiccated; protect from light and moisture |
| Lyophilised cartridge (short-term) | 2–8°C | Up to 4 weeks | Desiccated; suitable for active research use |
| Reconstituted in bacteriostatic water | 2–8°C | Up to 28 days | Benzyl alcohol preservative extends stability; in-pen use |
| Reconstituted aliquots (extended) | −80°C | Up to 12 months | Single-use aliquots; avoid repeated freeze-thaw cycles |
Frequently Asked Questions
Reviews
There are no reviews yet.